| MDL | - |
|---|---|
| Molecular Weight | 442.09 |
| Molecular Formula | C17H11BrCl2N2O3 |
| SMILES | O=C(NC1=CC=C(Cl)C=C1Cl)/C(C#N)=C/C2=CC(OC)=C(O)C(Br)=C2 |
Chst15-IN-1 is a potent reversible covalent Chst15 inhibitor. Chst15-IN-1 effectively inhibits chondroitin sulfate-E ( CS-E ) sulfation levels and other closely related glycosaminoglycans (GAG) sulfotransferases . Chst15-IN-1, as a selective sulfotransferase inhibitor, can diminish the inhibitory effects of chondroitin sulfate proteoglycans (CSPGs), and can be used for the stimulation of neuronal repair [1] .
Chst15 [1]
Chst15-IN-1 (25 μM; 24 hours; Neu7 astrocytes) is selective for sulfotransferases over the myriad of reactive cysteine-containing proteins. Chst15-IN-1 (10 and 25 μM; Neu7 astrocytes) shows a significant dose dependent decrease in cell-surface CS-E expression [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Chst15-IN-1 (3.0 mg/kg; i.v.) has a moderate clearance of 21 mL/min/kg, moderate volume of distribution of 0.97 L/kg, and short terminal half-life of 1.6 hours [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Rats |
| Dosage: | 3.0 mg/kg (Pharmacokinetic Analysis) |
| Administration: | I.v. |
| Result: | Had a moderate clearance of 21 mL/min/kg, moderate volume of distribution of 0.97 L/kg, and short terminal half-life of 1.6 h. |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 50 mg/mL ( 113.10 mM ; ultrasonic and warming and heat to 60°C)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.2620 mL | 11.3099 mL | 22.6198 mL |
| 5 mM | 0.4524 mL | 2.2620 mL | 4.5240 mL |
| 10 mM | 0.2262 mL | 1.1310 mL | 2.2620 mL |